European Commission Approves Soliris for Anti-AChR Antibody-Positive Refractory gMG
The European Commission (EC) has approved Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The approval of Soliris, marketed by Alexion Pharmaceuticals, follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of…